Publication of EUnetHTA 21 deliverable ”JCA without HTD submission”
EUnetHTA 21 is pleased to announce the publication of the EUnetHTA 21 deliverable ”JCA without HTD submission”. We thank everyone involved for their work on this important milestone of the project. More information as well as the documents can be found here: https://www.eunethta.eu/d5-4/
The EUnetHTA 21 Consortium will cease operations on 16 September 2023
The European Health and Digital Executive Agency (HADEA) signed the Service Contract for the Provision of Joint Health Technology Assessment (HTA) Work Supporting the Continuation of EU Cooperation on HTA (CHAFEA/LUX/2020/OP/0013) with the EUnetHTA 21 Consortium. The 24-month contract is due to expire on 16 September 2023 and the EUnetHTA 21 Consortium will cease operating […]
EUnetHTA 21 response to ARM article
In 2022 the EUnetHTA 21 Consortium worked together to produce a number of guidelineswhich outline the methods that are used to undertake Joint Clinical Assessments oftechnologies. Many of these guidelines are published on www.eunethta.eu and includedauthorship from experts from across EU Member States (MS) (12 MS were involved inEUnetHTA21 consortium) as well as consensus agreement […]
Publication of the EUnetHTA 21 – EMA work plan
EUnetHTA 21 is pleased to announce the publication of the EUnetHTA 21 – EMA work plan. EMA and EUnetHTA 21 work closely together, to prepare for the HTA Regulation. Between 2021 and 2023, EMA and EUnetHTA 21 are focusing on the following jointly agreed priority areas:
Publication of second Joint Clinical Assessment
The EUnetHTA 21 is pleased to announce the publication of their second Joint Clinical Assessment. One of the objective of the JCA production was to test the newly developed methodological guidelines as well as the revised templates and guidelines, in EUnetHTA 21. The JCA was conducted on the medical device on Evoke Spinal Cord Stimulation […]
Parallel EMA/HTA body (HTAb) Scientific Advice during Interim Period post EUnetHTA 21
The Parallel EMA/EUnetHTA 21 Joint Scientific Consultations (JSCs) under the EUnetHTA 21 service contract will have to be completed by September 2023 and all available slots have already been allocated. To bridge the interim period between the closure of EUnetHTA 21 and the full application of the HTA Regulation in January 2025, EMA and national […]
Public consultation for D6.2.1 and D6.4.1 is now open until 31.07.2023.
EUnetHTA 21 announces that the public consultation for the deliverables ‘’D6.2.1 Briefing Document Template’’ and ‘’D6.4.1 External Guidance with EMA’’ will be open for public consultation between 01.07.2023 – 31.07.2023, 23:59CEST. The draft deliverable as well as the comment form can be found via this link https://www.eunethta.eu/jointhtawork/. For more information on the process of the public […]
Publication of [draft] D5.4 deliverable.
The EUnetHTA 21 is pleased to announce the publication of the draft version of the D5.4 deliverable on medicinal JCA timelines. Please note, that this is a draft document and may be revised by August 2023. The draft document can be found here: https://www.eunethta.eu/d5-4/ The document will be discussed during the meeting on the 13th July 2023. […]
Publication of first Joint Clinical Assessment
The EUnetHTA 21 is pleased to announce the publication of their first Joint Clinical Assessment. One of the objective of the JCA production was to test the newly developed methodological guidelines as well as the revised templates and guidelines, in EUnetHTA 21. The JCA was conducted on the medical device Optilume® urethral drug-coated balloon (DCB), which […]
The EUnetHTA 21 Consortium will cease operations on 16 September 2023
The European Health and Digital Executive Agency (HADEA) signed the Service Contract for the Provision of Joint Health Technology Assessment (HTA) Work Supporting the Continuation of EU Cooperation on HTA (CHAFEA/LUX/2020/OP/0013) with the EUnetHTA 21 Consortium. The 24-month contract is due to expire on 16 September 2023 and the EUnetHTA 21 Consortium will cease operating […]
